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Pericytes are the major source of scar-producing
myofibroblasts following kidney injury; however, the
mechanisms of this transition are unclear. To clarify this, we
examined Collagen 1 (a1)-green fluorescent protein (GFP)
reporter mice (pericytes and myofibroblasts express GFP)
following ureteral obstruction or ischemia–reperfusion injury
and focused on the role of platelet-derived growth factor
(PDGF)-receptor (PDGFR) signaling in these two different
injury models. Pericyte proliferation was noted after injury
with reactivation of a-smooth muscle actin expression, a
marker of the myofibroblast phenotype. PDGF expression
increased in injured tubules, endothelium, and macrophages
after injury, whereas PDGFR subunits a and b were expressed
exclusively in interstitial GFP-labeled pericytes and
myofibroblasts. When PDGFRa or PDGFRb activation was
inhibited by receptor-specific antibody following injury,
proliferation and differentiation of pericytes decreased.
The antibodies also blunted the injury-induced transcription
of PDGF, transforming growth factor b1, and chemokine CCL2.
They also reduced macrophage infiltration and fibrosis.
Imatinib, a PDGFR tyrosine kinase inhibitor, attenuated
pericyte proliferation and kidney fibrosis in both fibrogenic
models. Thus, PDGFR signaling is involved in pericyte
activation, proliferation, and differentiation into
myofibroblasts during progressive kidney injury. Hence,
pericytes may be a novel target to prevent kidney fibrosis
by means of PDGFR signaling blockade.
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We have recently identified microvascular pericytes as the
primary source of collagen-producing myofibroblasts in
progressively fibrotic kidneys following unilateral ureteral
obstruction (UUO) or ischemia–reperfusion injury (IRI)
using both kinetic mathematical modeling and state-of-the-
art genetic fate-mapping studies.1,2 Pericytes form direct
communications with endothelial cells at peg and socket
junctions where direct cell–cell interaction has been reported
to occur.3–5 With the increase of collagen 1 (a1) (Col1a1)
transcript, pericytes start to move away from capillaries, enter
cell cycle, and subsequently increase in population size,
within 24 h following kidney injury by UUO surgery.1,6 All
pericytes in the healthy adult kidney express platelet-derived
growth factor receptor b (PDGFRb) that continues to be
expressed in all myofibroblasts in fibrotic kidney.1,2,6
Although interrupting PDGFR signaling has been shown to
result in significant delay in wound closure and attenuation
of experimental kidney fibrosis,7,8 it is unclear whether
PDGFR signaling activates pericyte–myofibroblast transition
in injured kidneys.
The fact that pericytes are a major source of myofibro-
blasts serves to readjust the focus of fibrosis research to areas
that are potentially of more importance in the progression of
kidney disease, including the cross-talk between pericytes and
endothelial cells of the peritubular capillaries.6,9 Indeed,
ureteral obstruction of the kidney is known to result in
downregulation of renal blood flow and glomerular filtration
rate, suggesting that circulating factors may be important
triggers activating pericyte responses.10,11 Pericytes have been
reported to serve as paracrine cells supporting vascular
integrity and providing important angiogenic factors includ-
ing vascular endothelial growth factor and angiopoietin
1.12–14 Reciprocally, endothelial cells are the source of PDGF
and transforming growth factor b1 (TGFb1).15 A lack of
pericytes has been associated with aneurysm formation,
leaky vessels, and spontaneous hemorrhage.4,16 Vice versa,
endothelial cell-derived PDGF is crucial for pericyte
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recruitment along developing vasculature.5,16 In addition to
endothelial cells, tubular epithelial cells and recruited
inflammatory macrophages are the important PDGF
sources.8,17
The role of PDGFR signaling in kidney disease has been
reviewed in detail.8 PDGFR signaling consists of four ligands
(PDGF-A, -B, -C, and -D) and two receptors (PDGFR-a and
PDGFR-b). PDGFR possesses tyrosine kinase activity and
is autophosphorylated upon ligand binding. Activated
signaling will be transduced to activate various proto-
oncogenes and immediate-early response genes responsible
for particular functions.18 The components of PDGF–PDGFR
system are expressed constitutively or inducibly in kidneys,
including endothelial cells, tubular epithelial cells, and
interstitial cells.19–25 Altered expression is characterized in
almost all experimental and human kidney diseases. Inter-
vention studies identified PDGF-C as a mediator of renal
interstitial fibrosis and PDGF-B and PDGF-D as key factors
involved in both mesangioproliferative disease and interstitial
fibrosis.23–26
Collagen 1 (a1)-green fluorescent protein (GFP;
Coll-GFP) reporter mice express high levels of GFP in
interstitial pericytes and myofibroblasts in normal and
fibrogenic kidneys, respectively. a-Smooth muscle actin
(aSMA) is a robust marker of differentiated myofibroblasts
in the adult kidney, but is not expressed by adult pericytes.1,2
Using Coll-GFP mice, we aimed to study the expression of
PDGFR subunits in pericytes and myofibroblasts, the role
of PDGFR signaling in pericyte–myofibroblast transition in
kidneys after ureteral obstruction or IRI, and whether
blocking pericyte activation by PDGFR blockade may prevent
interstitial kidney fibrosis.
RESULTS
PDGFRs are activated in kidneys after UUO surgery
PDGF isoform and PDGFR subunit transcript levels increased
as UUO kidney injury progressed (Figure 1a), accompanied
by marked increases in PDGFRa and PDGFRb protein
levels (Supplementary Figure S1 online). Western blot
analyses for PDGF-B and PDGF-C, the two PDGF ligands
implicated in interstitial fibrosis,23,24 showed similar upre-
gulation (Supplementary Figure S1A online). In Coll-GFP
reporter mice, transcripts of GFP and Col1a1 increased
comparably in kidneys after UUO surgery (Supplementary
Figure S2A online). Increased Col1a1 transcript dictated the
increase of Col1a1 protein in both Coll-GFPþ myofibro-
blasts and extracellular area at day 4 after UUO surgery
(Supplementary Figure S2B online). In normal Coll-GFP
mice, GFP was detected in interstitial pericytes and
glomerular podocytes of the kidney, whereas fibrogenic
injury led to differentiation of pericytes into myofibroblasts
(Figure 1b and c). Pericytes and interstitial myofibroblasts in
normal and UUO kidneys, respectively, expressed PDGFRa
and PDGFRb exclusively, but did not express PDGF-B or
PDGF-C (Figure 1b and d). Mesangium also expressed
PDGFRb, but PDGFRa was not detected in glomeruli (Figure
1c). PDGF-B isoform, the major ligand for receptors
composed of PDGFRa and/or PDGFRb, was not detected
by immunofluorescence in normal kidney, whereas its
expression was readily detected in tubules, endothelial cells,
and macrophages of UUO kidney (Figure 1d and Supple-
mentary Figure S3A and B online). PDGF-C isoform, the
ligand for PDGFRa, was weakly detected in macrophages of
normal kidney, and it had markedly increased expression in
macrophages, but not in epithelial tubules or endothelial
cells, of UUO kidney (Figure 1e and Supplementary Figure
S3C online). Phosphorylation of PDGFRa and PDGFRb
increased with time after UUO surgery (Supplementary
Figure S1 online). In normal kidney, a proportion of
PDGFRb is consistently phosphorylated, unlike PDGFRa.
Anti-PDGFR antibody inhibits activation of cognate
PDGFR in vitro and in vivo
To verify the specificity of anti-PDGFRa (1E10) and
anti-PDGFRb (2C5) antibodies, we stimulated primary
cultured UUO kidney myofibroblasts in vitro using PDGF-
AA or PDGF-BB in the presence of anti-KLH control
antibody (KLH), 1E10, or 2C5. Short-term stimulation
increased receptor phosphorylation but not the level of total
PDGFRa or PDGFRb protein (Supplementary Figure S4
online). PDGF-AA-stimulated phosphorylation of both
PDGFRa and PDGFRb was inhibited by 1E10, indicating that
1E10 was specific for PDGFRa blockade and PDGF-AA-ligated
PDGFRa might transactivate PDGFRb (Supplementary
Figure S4A online). PDGF-BB-stimulated phosphorylation of
PDGFRb was inhibited by 2C5 (Supplementary Figure S4B
online). The expression of both PDGFRa and PDGFRb
increased in UUO kidneys of KLH-treated animals, whereas
the increase in both receptors was attenuated in 1E10- or
2C5-treated mice. 1E10 and 2C5 in combination synergisti-
cally prevented PDGFRa and PDGFRb phosphorylation
(Figure 2a and b). Injury-stimulated phosphorylation of
PDGFRa and PDGFRb in UUO kidneys was also attenuated
by either 1E10 or 2C5 (Figure 2a and c).
Anti-PDGFR antibody administration to mice attenuates
kidney fibrogenesis
Because there is an exponential increase of interstitial
Coll-GFPþ cells from day 0 through day 4 and peak
proliferation occurs at day 2 after UUO or IRI surgery,1 we
studied the inhibitory effect of anti-PDGFR antibodies on
Coll-GFPþ cells at day 4 and fibrosis at day 14 after surgery.
Interstitial Coll-GFPþ cells in UUO kidneys of mice
administered with KLH control antibody increased in
population markedly, and 97.4% of them expressed a-SMA
by immunofluorescence, indicative of myofibroblast differ-
entiation at day 4 after surgery (Figure 3a–c). Administration
of 1E10 and 2C5 antibodies decreased the number of
interstitial Coll-GFPþ cells by 36 and 43%, respectively
(Figure 3a and b). This inhibition was recapitulated in the cell
number of aSMAþ ;Coll-GFPþ myofibroblasts (Figure 3a
and c). Compared with 1E10 or 2C5 treatment alone, no
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enhanced effect of combining both anti-PDGFR antibodies
on the myofibroblast population was noted (Figure 3b and c).
Only 0.9% of total kidney cells were Coll-GFPþ ;PDGFRaþ
in normal kidney analyzed by flow cytometry, whereas the
percentage increased markedly to 12.4% in UUO kidney
of KLH-treated mice (Supplementary Figure S5 online).
Treatment with 1E10 or 2C5 antibodies decreased the
percentage to 7.3 and 7.7%, respectively (Supplementary
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Figure S5 online). To determine myofibroblast differentia-
tion, Coll-GFPþ ;PDGFRaþ cells were further analyzed for
aSMA expression by flow cytometry. Very low level of aSMA
was detected in 0.7% of Coll-GFPþ ;PDGFRaþ cells in
normal kidney, whereas the expression was increased and
detected in 71.2% of Coll-GFPþ ;PDGFRaþ cells in UUO
kidney of KLH-treated mice (Figure 3d and e). Antibodies
1E10 and 2C5 decreased not only the aSMA-expressing cells
to 47.4 and 44.4%, respectively, but also the mean peak
fluorescence level (Figure 3d and e). Quantitative PCR
(Q-PCR) showed a 15- to 20-fold increase of Col1a1, Col3a1,
and aSMA transcripts in UUO kidney compared with normal
kidney, and this was markedly downregulated by either 1E10
or 2C5 administration (Figure 4a). 1E10 together with 2C5
produced no significant additional effect. Expression of
whole kidney aSMA protein or GFP protein was attenuated
by 1E10 or 2C5 antibodies (Figure 4b). To study the effect of
anti-PDGFR antibody on differentiation of pericytes into
myofibroblasts, we purified pericytes or myofibroblasts
by sorting Coll-GFPþ ;PDGFRaþ cells from normal or
UUO kidneys, respectively, in antibody-treated animals
(Supplementary Figure S5A online). Q-PCR showed 3- and
18-fold increase of Col1a1 and aSMA transcripts, respectively,
in UUO kidney myofibroblasts purified from KLH-treated
animals, which were markedly downregulated in myofibro-
blasts purified from either 1E10- or 2C5-treated animals
(Figure 4c). Pericytes in normal kidney did not express
detectable aSMA protein by immunofluorescence, although
very low levels of aSMA transcript were detected by Q-PCR
(Figures 3a and c and 4c). The consequence of inhibition of
pericyte–myofibroblast differentiation and Col1a1 transcrip-
tion in myofibroblasts was a 70% attenuation of kidney
fibrosis at 14 days after UUO surgery with 1E10 or
2C5 antibodies compared with KLH-treated animals
(Supplementary Figure S6 and Figure 4d online). Both
1E10 and 2C5 antibodies decreased the collagen deposition
significantly (Supplementary Figure S6 and Figure 4d
online). Next, we detected the pan cell-cycle marker Ki67.
In KLH-treated mice, 32.2% of interstitial Coll-GFPþ cells
in UUO kidneys were in cell cycle day 4 after surgery
(Supplementary Figure S7 and Figure 5a online). Adminis-
tration of 1E10 or 2C5 antibodies decreased the number
of proliferating interstitial Coll-GFPþ cells by 34 and
38%, respectively (Supplementary Figure S7 and Figure 5a
online). Both PDGFR antibodies inhibited upregulation of
PDGF isoform and TGFb1 transcripts in UUO kidneys
(Figure 5b–f).
TGFb1, not PDGF, stimulates myofibroblast differentiation
from pericytes in vitro
UUO kidney myofibroblasts cultured in vitro on glass
appeared spindle shaped and expressed aSMA and vimentin
in the absence or presence of PDGF or TGFb1 (Figure 6a).
However, only TGFb1 further increased Col1a1 and aSMA
transcripts (Figure 6b). Pericytes purified from normal
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Figure 2 |Anti-platelet-derived growth factor receptor (PDGFR)
antibody inhibited PDGFR expression. (a) Representative images
were that of western blot of whole kidney lysates for tyrosine
phosphorylation of PDGFRa (p-PDGFRa) and PDGFRb (p-PDGFRb),
and their total forms from mice treated with control (KLH), anti-
PDGFRa (1E10), anti-PDGFRb (2C5), or combination treatment
(1E10þ 2C5). C and U denote control and UUO kidneys at day 4
after surgery, respectively. (b, c) Expression levels were normalized
by b-actin. wPo0.01, zPo0.001. N¼ 6/group.
Figure 1 |Platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) increased expression in kidneys after unilateral
ureteral obstruction (UUO). (a) Quantitative PCR (Q-PCR) time course for transcripts of whole kidney PDGF isoforms and PDGFR subunits
following UUO surgery. Expression levels were normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH). wPo0.01, zPo0.001
versus normal kidney at day 0 (d0). N¼ 3/time point. (b) Immunofluorescence images showing that PDGFRa and PDGFRb were expressed
exclusively in interstitial Coll-GFPþ cells of normal control (CON) and UUO kidneys at day 4 after surgery. (c) Immunofluorescence images
showing that PDGFRb, but not PDGFRa, was expressed in glomerular mesangium of CON and UUO kidneys at day 4 after surgery in Coll-GFP
mice whose glomerular podocytes expressed Coll-GFP. (d) Immunofluorescence images showing PDGF-B in epithelial cells of dilated
tubules of day 4 UUO kidney (denoted by T), not in Coll-GFPþ cells. PDGF-B was difficult to detect in CON kidney. (e) Immunofluorescence
images showing that PDGF-C was expressed in F4/80þ macrophages of day 4 UUO kidney, but in a very low level in F4/80þ macrophages
of CON kidney (arrow) and not in tubular epithelial cells (denoted by T). Scale bar¼ 25mm.
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kidneys of Coll-GFP mice and cultured on glass were spindle
shaped and continued to express GFP (Figure 6c). All
pericytes expressed vimentin, but aSMA was not detected.
After stimulation by TGFb1, but not by PDGF, aSMA was
markedly increased at both the protein and transcriptional
levels (Figure 6c and d).
Anti-PDGFR antibody decreases macrophage infiltration
A fivefold increase of F4/80þ macrophages was noted in
UUO kidneys of KLH-treated mice at day 4 after surgery
(Figure 7a and b). Administration of 1E10 or 2C5 antibodies
resulted in reduction of macrophage cell number by 60 and
54%, respectively (Figure 7a and b). Q-PCR for CCR2
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Figure 3 |Anti-platelet-derived growth factor receptor (PDGFR) antibody inhibited pericyte–myofibroblast transition. (a) Confocal
microscopic images of interstitial Coll-GFPþ cells colabeled with myofibroblast marker a-smooth muscle actin (aSMA) in kidneys at day 4
after surgery. Arrows indicate aSMA;Coll-GFPþ cells. Scale bar¼ 25 mm. (b, c) Quantification of (b) interstitial Coll-GFPþ cells and
(c) aSMAþ ;Coll-GFPþ myofibroblasts in high-powered field (HPF) at  400 magnification. N¼ 6/group. (d, e) Fluorescence-activated
cell sorting (FACS) analysis showing aSMA expression (white) in Coll-GFPþ ;PDGFRaþ cells of control (CON) and unilateral ureteral
obstruction (UUO) kidneys from mice treated with KLH, 1E10, or 2C5. Coll-GFPþ ;PDGFRaþ cells were sorted as described in
Supplementary Figure S5A online. Isotype control is shown in black. (d) Representative plots are one of three independent experiments.
Quantification of aSMAþ cells in Coll-GFPþ ;PDGFRaþ cells (%) analyzed by FACS is shown in e. N¼ 3/group. wPo0.01, zPo0.001.
1174 Kidney International (2011) 80, 1170–1181
or ig ina l a r t i c l e Y-T Chen et al.: PDGFR signal activates pericytes in kidney fibrosis
(chemokine (C-C motif) receptor 2) and CX3CR1 (CX3C
chemokine receptor 1) transcripts in UUO kidneys indicated
that upregulation of these myeloid-restricted transcripts in
KLH-treated mice was attenuated by either 1E10 or 2C5
antibodies (Figure 7c and d). In addition, either of the
anti-PDGFR antibodies inhibited the injury-stimulated
upregulation of monocyte–macrophage chemoattractant
CCL2 (chemokine (C-C motif) ligand 2) transcripts
(Figure 7e). We were intrigued by the possibility that
macrophages possess receptors that enable a direct response
to PDGF ligands. Unlike kidney myofibroblasts, bone
marrow-derived macrophages, when analyzed by flow
cytometry, did not express PDGFRa or PDGFRb (Supple-
mentary Figure S8A online), and confocal microscopic
images of immunostained sections did not detect PDGFRa
or PDGFRb in kidney macrophages in vivo (Supplementary
Figure S8B online).
Imatinib inhibits PDGFR signaling in pericytes and
attenuates kidney fibrosis
After demonstrating that disruption of PDGFR signaling in
pericytes attenuated kidney fibrosis by receptor-specific
antibodies, we tested the efficacy of a clinically applicable
tyrosine kinase inhibitor, imatinib mesylate, in the same
kidney fibrosis model. Compared with vehicle, imatinib
decreased both PDGFRa and PDGFRb phosphorylation and
Coll-GFP expression in UUO kidneys (Figure 8a and b).
Imatinib decreased the expanded population of both
Coll-GFPþ cells and aSMAþ ;Coll-GFPþ myofibroblasts
by inhibiting cell proliferation (Figure 8c–e and Supplemen-
tary Figures S9 and S10 online), and attenuated macrophage
infiltration (Figure 8f and Supplementary Figure S11 online)
and fibrosis development in UUO kidneys (Figure 8g and
Supplementary Figure S12 online). These antifibrogenic
properties could not be attributed to c-kit inhibition in
pericytes–myofibroblasts because these cells do not express c-
kit (Supplementary Figure S13 online).
Blockade of PDGFR signaling attenuates IRI-induced
kidney fibrogenesis
To determine whether the antifibrogenic properties of
PDGFR signaling blockade is generalizable to other models
of cortical and medullary injury to the kidney, we studied
their properties in a second fibrogenic model that we have
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Figure 4 |Anti-platelet-derived growth factor receptor (PDGFR) antibody attenuated kidney fibrosis. (a) Quantitative PCR (Q-PCR) of
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previously reported, the unilateral IRI model.1,6,27 Single
kidneys exposed to IRI develop progressive interstitial fibrosis
by day 14. Similar to the studies on UUO injury, IRI kidneys
from mice with imatinib administration experienced
considerably fewer total interstitial Coll-GFPþ cells and
fewer aSMAþ ;Coll-GFPþ myofibroblasts on days 4 and
14 post IRI (Supplementary Figure S14A–D online). The
consequence of blocking of Coll-GFPþ myofibroblast
appearance was marked attenuation of interstitial fibrosis
on day 14 post IRI (Supplementary Figure S14E and F
online), similar to our observations in the UUO kidney
injury model.
DISCUSSION
These studies highlight the efficacy of strategies to block
PDGFRa and PDGFRb signaling in response to ischemic
or mechanical injury in mouse adult kidney. Anti-
body-mediated blockade or small-molecule inhibition of
tyrosine phosphorylation of the PDGFRs is sufficient to
attenuate the development of interstitial fibrosis by 470%.
Moreover, single receptor blockade prevents recruitment of
inflammatory macrophages to the kidney. Macrophages are
inflammatory cells that contribute to progression of fibrosis
in these models.17,27 These studies therefore point to
PDGFRa or PDGFRb as potential candidates for therapies
in human ischemic or other kidney injuries.
In our experiments, PDGFRa is exclusively expressed by
kidney pericytes and PDGFRb is expressed by kidney
pericytes, as well as by mesangial cells of the glomerulus
and vascular smooth muscle of kidney arterioles. Strikingly,
these receptors are neither expressed by recruited leukocytes
nor by epithelium or endothelium. Therefore, it is notable in
the injury models reported here, which do not focus on the
glomerulus, that targeting single receptors restricted to
pericytes is sufficient to prevent fibrosis and inflammation.
These findings support previous studies that have identified
pericytes of the peritubular capillaries as the major source of
myofibroblasts.1,2
In accordance with previous studies,19–25 PDGF ligand
expression was low in normal kidneys, but increased
markedly and rapidly in endothelial cells, tubular epithelial
cells, and macrophages after ureteral ligation. Although 1E10
and 2C5 antibodies specifically inhibited PDGF-stimulated
activation of PDGFRa and PDGFRb in vitro, respectively,
each produced comparable inhibition of phosphorylation
of both PDGFRa and PDGFRb in vivo. This might be
the consequence of their comparable capacity to inhibit
the expression of PDGF isoforms induced by injury,
especially PDGF-B and PDGF-C, the two important PDGF
ligands previously implicated in interstitial fibrosis. There-
fore, either anti-PDGFRa or anti-PDGFRb antibody
administration has the capacity to cross-inhibit the other
receptor-signaling pathway in vivo through downregulation
of PDGF ligands.
Microvascular Coll-GFPþ pericytes did not express
aSMA in normal kidney, whereas, following ureteral
obstruction, almost all interstitial Coll-GFPþ cells expressed
aSMA indicative of differentiation to myofibroblasts at
4 days after injury onset. These studies are the first to show
that anti-PDGFR antibody administration markedly de-
creased the number of aSMAþ myofibroblasts in UUO
kidneys, and in addition show, by flow cytometry, that anti-
PDGFR antibody treatment also downregulates overall aSMA
expression in individual purified Coll-GFPþ ;PDGFRaþ
cells from UUO kidney. In vivo, there was a role of PDGFR
signaling in inducing aSMA expression and myofibroblast
differentiation. In vitro cultured pericytes increased aSMA
expression after TGFb1 stimulation but not after PDGF
treatment, suggesting that PDGF alone might not be
sufficient to induce pericyte–myofibroblast transition. Our
data showed that anti-PDGFR antibody treatment inhibited
upregulation of TGFb1 in injured kidney. This finding
supports a hypothesis that TGFb1 may be an important
contributing cytokine in transducing activated PDGFR
signaling in pericyte–myofibroblast transition in vivo.28,29
Further studies will be required to dissect this potential
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cooperation of these cytokine-signaling pathways in the
pericyte.
It is increasingly clear that renal fibrosis is not only a
passive deposition of extracellular matrix but also involves
active inflammation.30 Consistent with this, a significant
fibrosis reduction has been demonstrated in murine renal
fibrosis models through selective macrophage ablation or
functional regulation, by chemokine mutation or blockade of
chemokine receptors.17,27,31–33 PDGFR signaling activated
by PDGF-B or PDGF-C has been shown to regulate the
production of proinflammatory chemokines by renal myofi-
broblasts including CCL2 and CCL5.24,34 In agreement with
this, our data showed that injury-stimulated expression of
CCL2 was inhibited by PDGFR antibody. Both CCR2 and
CX3CR1 transcripts were downregulated by PDGFR block-
ade, suggestive of a reduction of both proinjurious and
profibrotic macrophage subpopulations.17,27 Our studies here
indicate that PDGF ligands are not mitogens for macro-
phages, because macrophages expressed neither PDGFRa
nor PDGFRb. Therefore, the inhibition of macrophage
infiltration was most likely secondary to the downregulation
of chemokines. Our previous studies have shown that
macrophages, especially Ly6Clow macrophages (also known
as the CX3CR1high sub-population), could stimulate myofi-
broblast proliferation and extracellular matrix production in
progressive kidney or liver fibrosis.17,27,31,35 Ly6Clow macro-
phages are one of the major cell types in the interstitium
producing both PDGF ligands and TGFb1.17 In these studies,
the decrease in inflammatory macrophages, triggered by
PDGFR-specific antibodies, is sufficient to account for the
downregulation of injury-stimulated PDGF and TGFb1.
Although the small-molecule imatinib was developed
primarily to inhibit c-abl kinase, it also inhibits PDGFR
kinase activity, and therefore signaling, at comparable half-
maximal inhibitory concentration.36 Its beneficial effect has
been demonstrated in many animal models of kidney disease,
including UUO kidney fibrosis in rats,37 lupus nephritis,
cryoglobulinemic glomerulonephritis, and diabetic nephro-
pathy in mice.38–40 In addition to reducing macrophage
infiltration, this study identified that imatinib attenuates
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kidney fibrosis by inhibiting pericyte activation in injured
kidneys. Our findings suggest strongly that this beneficial
effect on the kidney is due to the direct inhibition of PDGFR
tyrosine kinase activity in pericytes, as pericytes were not
found to express the receptor c-kit. However, c-kit was
identified in epithelial cells reproducing findings reported
elsewhere.41 It is currently not clear whether c-kit inhibition
on tubular epithelial cells by imatinib has any bearing on its
antifibrogenic properties.
Although reports have previously identified epithelial cells
and circulating cells as major direct contributors to kidney
myofibroblasts,42,43 extensive studies from our laboratories,
those of our collaborators, and several independent investi-
gators, using different state-of-the-art genetic fate-mapping
strategies and other stringent techniques, in several different
models of kidney injury, have not supported those earlier
reports.1,2,6,9,27,44–56 Our laboratories and those of our
collaborators only find kidney pericytes and perivascular
fibroblasts derived from embryonic FoxD1þ cap metaneph-
ric mesenchyme as cells that become scar-forming myofi-
broblasts. This Discussion is not the appropriate forum to
review and debate the newly published fate-mapping findings
with the earlier studies, as these have already been discussed
in many peer-reviewed journals.1,2,6,9,27,44–56 Regardless of
the precise origins of myofibroblasts, the studies presented in
these pages, inspired by the newly discovered pathological
role of kidney pericytes, firmly and unequivocally identify a
large population of PDGFRa- and PDGFRb-expressing cells
that are kidney pericytes, and blockade of the receptors on
these cells prevents development of interstitial inflammation
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and kidney fibrosis in two clinically relevant models of kidney
injury in mice.
In conclusion, this report provides new evidence that
activated PDGFR signaling leads to the proliferation and
differentiation of pericytes into myofibroblasts in progressive
kidney disease and identifies pericytes as a novel therapeutic
target to prevent fibrosis development by PDGFR blockade.
MATERIALS AND METHODS
Mouse models of kidney fibrosis
UUO was performed in adult (8–12 weeks) C57BL6 wild-type or
Coll-GFP mice as described previously.1 Briefly, the left ureter
was ligated twice using 4-0 nylon surgical sutures at the level of the
lower pole of the kidney. The unilateral IRI model was performed as
previously described using a 30-min ischemic time at 36.8–37.3 1C
core temperature.27 All animal studies were carried out under
a protocol approved by the institutional animal care and use
committee, National Taiwan University, College of Medicine.
Coll-GFP mice
Coll-GFP transgenic mice generated on the C57BL6 background
were as described previously.1 In brief, 3.2 kb of the Col1a1
promoter and enhancer with the open reading frame of EGFP
yielded highest levels of GFP expression when Col1a1 transcripts
were generated.
Anti-PDGFR antibody treatment
Mice were treated with control (KLH), anti-PDGFRa (1E10), anti-
PDGFRb (2C5), or a combination of 1E10 and 2C5 (40mg/kg
intraperitoneally, ImClone Systems, New York, NY) 2 h before
surgery, and then every other day until killing on days 4 and
14 (N¼ 6 for each group).57,58
Imatinib mesylate treatment
Mice were treated by gavages with vehicle or imatinib mesylate
(50mg/kg, Novartis Pharmaceuticals, Basel, Switzerland) 2 h before
surgery, and then twice a day until killing on days 4 and 14
(N¼ 6 for each group).
Purification and culture of pericytes from normal kidney
Pericyte purification from normal kidney was described previously.1
Briefly, the kidney was diced, incubated at 37 1C for 30min
with liberase (0.5mg/ml, Roche, Mannheim, Germany) and DNase
(100U/ml, Roche) in Hank’s buffered salt solution. After centrifu-
gation, cells were resuspended in 5ml of phosphate-buffered saline/
1% bovine serum albumin, and filtered (40mm). Pericytes were
purified by isolating GFPþ ;PDGFRaþ cells using FACSAria cell
sorting (BD Biosciences, San Jose, CA), and then total RNA was
isolated or cultured in Dulbecco’s modied Eagle’s medium with 20%
fetal bovine serum. After 4 days, the pericytes were then treated with
PDGF-AA, PDGF-BB, or TGFb1 (10 ng/ml, R&D Systems, Minnea-
polis, MN), or no additional treatment in Dulbecco’s modied Eagle’s
medium with 1% fetal bovine serum. After 2 days, cells were fixed
with 4% paraformaldehyde for 5min for immunofluorescence study
or subjected to total RNA extraction.
Purification and culture of myofibroblasts from kidney
Purification of kidney myofibroblasts from kidney at day 7 after
UUO was described previously.1 The kidney was diced and
incubated at 37 1C for 1 h with liberase (0.5mg/ml) and DNase
(100U/ml) in Hank’s buffered salt solution. After centrifugation,
cells were resuspended in 5ml of phosphate-buffered saline/1%
bovine serum albumin and filtered (40 mm). Myofibroblasts were
purified by isolating GFPþ ;PDGFRaþ cells using FACSAria cell
sorting and then total RNA was isolated, or purified cells were
cultured in Dulbecco’s modied Eagle’s medium with 20% fetal
bovine serum. The primary cultured cells used in this study were
between passages 4 and 6 and have been characterized previously.1
Fluorescence-activated cell sorting (FACS) analysis
Bone marrow-derived macrophages and UUO kidney myofibro-
blasts were resuspended in FACS buffer and incubated
with antibodies against PDGFRa, PDGFRb, CD11b, or F4/80
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(1:200, eBioscience, San Diego, CA) for 30min at 4 1C in the
presence of 1% mouse serum. Cells were then analyzed using BD
FACSCalibur flow cytometer.17 To analyze aSMA expression in
kidney Coll-GFPþ ;PDGFRaþ cells, single cells were fixed in 4%
paraformaldehyde/phosphate-buffered saline for 10min with
shaking at 4 1C, and then permeabilized in 0.1% saponin/
phosphate-buffered saline for 10min. After washing, the single cells
were incubated with antibodies against PDGFRa (1:200,
eBioscience), aSMA, or isotype control (1:20, R&D Systems) for
30min. Thereafter, cells were analyzed using flow cytometer.
In vitro analysis of anti-PDGFR antibody
UUO kidney myofibroblasts were cultured in Dulbecco’s modied
Eagle’s medium with 0.5% fetal bovine serum for 16 h, and then
incubated with PDGF-AA or PDGF-BB (10 ng/ml, R&D Systems) in
the presence of KLH, 1E10, or 2C5 (100 mg/ml) for 15min. The
extent of PDGFRa or b phosphorylation was determined by western
blot analysis.
Tissue preparation and histology
Mouse tissues were prepared and stained as previously described.1
Primary antibodies against the following proteins were used
for immunolabeling: F4/80, CD31 (1:200, eBioscience), Ki-67,
PDGF-B (1:200, Abcam, Cambridge, UK), vimentin, PDGF-C
(1:200, Santa Cruz Biotechnology, Santa Cruz, CA), and aSMA-Cy3
(1:200, clone 1A4, Sigma, St Louis, MO). Fluorescent-conjugated
secondary antibody labeling (1:400–1:800, Jackson Immuno-
research, West Grove, PA), colabeled with DAPI (4,6-diamidino-2-
phenylindole), mounting with Vectashield/DAPI (Vector Laboratories,
Burlingame, CA), image capture, and processing were carried out as
previously described. Quantification of specific cells in tissue sections
was carried out as described previously.6 Specific cells were counted in
10 cortical interstitial fields randomly selected at  400 magnification
(high-powered field) per mouse. Interstitial fibrosis was quantified in
picrosirius red-stained paraffin sections.
Quantitative-PCR
cDNA was synthesized using oligo(dT) and random primers.
Conventional PCR and Q-PCR were performed using methods
described previously.1 The specific primer pairs used in PCR are
listed in Supplementary Table S1 online.
Western blot analysis
Total cellular protein was subjected to western blot analysis using
methods described previously.59 The following primary antibodies were
used to detect the specific protein: Tyr754 phospho-PDGFRa, Tyr751
phospho-PDGFRb, PDGFRa and PDGFRb (Cell Signaling Technology,
Beverly, MA), PDGF-B (Abcam), PDGF-C (Santa Cruz Biotechnol-
ogy), and GFP (Medical & Biological Laboratories, Nagoya, Japan).
Statistical analysis
Data were expressed as mean±s.e., and analyzed using GraphPad
Prizm (GraphPad Software, San Diego, CA). The statistical
significance was evaluated by one-way analysis of variance.
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